Mobia Medical (NASDAQ:MOBI) Raised to Hold at Zacks Research

Mobia Medical (NASDAQ:MOBI) was upgraded by analysts at Zacks Research to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Several other brokerages have also weighed in on MOBI. JPMorgan Chase & Co. assumed coverage on shares of Mobia Medical in a research note on Tuesday. They set an “overweight” rating and a $15.00 target price for the company. Wolfe Research assumed coverage on shares of Mobia Medical in a research note on Tuesday. They set an “outperform” rating for the company. Bank of America assumed coverage on shares of Mobia Medical in a research note on Tuesday. They set a “buy” rating and a $16.00 target price for the company. BTIG Research assumed coverage on shares of Mobia Medical in a research note on Tuesday. They set a “buy” rating and a $19.00 target price for the company. Finally, Wall Street Zen raised shares of Mobia Medical to a “hold” rating in a research note on Saturday, May 16th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.25.

Mobia Medical Stock Up 0.8%

Shares of MOBI stock opened at $13.84 on Wednesday. The stock has a market cap of $457.90 million, a price-to-earnings ratio of 66.00 and a beta of 2.84. Mobia Medical has a 1-year low of $10.19 and a 1-year high of $14.77.

Mobia Medical (NASDAQ:MOBI) last announced its earnings results on Thursday, June 4th. The company reported $999.00 earnings per share for the quarter.

Insiders Place Their Bets

In other Mobia Medical news, Director Cynthia L. Lucchese acquired 125,000 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $15.00 per share, with a total value of $1,875,000.00. Following the completion of the purchase, the director owned 125,000 shares in the company, valued at $1,875,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William T. Harrington acquired 533,333 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $15.00 per share, with a total value of $7,999,995.00. Following the purchase, the director owned 2,006,716 shares of the company’s stock, valued at approximately $30,100,740. This trade represents a 36.20% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 1,268,332 shares of company stock valued at $19,024,980.